Pagoclone safe?

A reader to this blog sent me an interesting article on the potential for abuse of Pagoclone. The authors are Harriet de Wit, Lisa Vicini, George M. Haig, Thomas Hunt, and Douglas Feltner (Note that some are associated to Pfizer, which is a rival company of Indevus, the producer of Pagoclone, as far as I am aware of). Briefly, they compare Pagoclone to Diazepam (also an anti-anxiety drug). They suggest that Pagoclone is relatively safe to use with some effect on mood, subjective and objective sedation, similar to Diazepam. And a similar (relatively low) potential of abuse. Though the picture may change a bit as the effect is dependent on the actual dosis.

Judge for yourself...

Evaluation of the Abuse Potential of Pagoclone, a Partial GABAA Agonist

This study assessed the abuse potential of pagoclone, a partial agonist at the g-aminobutyric acid type A (GABAA) benzodiazepine receptor site, in healthy recreational drug users. Twenty-three young adults, who reported past recreational use of sedative drugs or alcohol, participated in 4 sessions during which capsules containing pagoclone (doses: 1.2 mg, the higher end of the proposed therapeutic dose range, and 4.8 mg, a 4-fold higher dose), diazepam (dose, 30 mg), or placebo were randomly administered under double-blind conditions. Subjective ratings of mood, drug effects, and psychomotor tests were completed at regular intervals after ingesting the capsules. On most of the standardized measures of abuse potential, pagoclone (dose, 4.8 mg) was rated as being similar to diazepam. Both drugs increased the ratings of good effects and drug liking. However, pagoclone also produced some adverse mood effects that might limit its potential to be used recreationally, and it produced fewer sedativelike effects on some measures. In general, the results with these doses indicate that the abuse potential of pagoclone is similar to that of diazepam, although its profile as a partial agonist suggests that differences between the drugs may emerge at higher doses.

( from Journal of Clinical Psychopharmacology Volume 26, Number 3, June 2006)